LCM
RAPP

Legato Capital Management’s Rapport Therapeutics RAPP Stock Holding History

Legato Capital Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$880K Buy
+21,124
New +$776K 0.07% 381

Other funds holding RAPP

JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Legato Capital Management's RAPP Position: Q2 2026 in Review

Legato Capital Management opened a new position in Rapport Therapeutics (RAPP) in Q2 2026: 21,124 shares worth $880K. The stake represents 0.07% of the portfolio and ranks #381 among its holdings.

39 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Legato Capital Management held 21,124 shares of Rapport Therapeutics worth $880K as of Q2 2026.
  • Rapport Therapeutics was a new Legato Capital Management position in Q2 2026.
  • Rapport Therapeutics made up 0.07% of Legato Capital Management's portfolio in Q2 2026, its #381 holding.
  • 39 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.